Compare SBGI & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBGI | PSNL |
|---|---|---|
| Founded | 1986 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 998.0M | 1.1B |
| IPO Year | 2023 | 2019 |
| Metric | SBGI | PSNL |
|---|---|---|
| Price | $15.09 | $13.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $22.00 | $12.20 |
| AVG Volume (30 Days) | 516.1K | ★ 3.5M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.56% | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $3,169,000,000.00 | $69,648,000.00 |
| Revenue This Year | $12.37 | $15.34 |
| Revenue Next Year | N/A | $41.46 |
| P/E Ratio | $50.89 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.89 | $3.84 |
| 52 Week High | $17.88 | $14.07 |
| Indicator | SBGI | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 61.69 | 73.30 |
| Support Level | $14.54 | $7.26 |
| Resistance Level | $15.49 | N/A |
| Average True Range (ATR) | 0.60 | 0.96 |
| MACD | 0.13 | 0.28 |
| Stochastic Oscillator | 92.59 | 90.77 |
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.